What Happens to a Stock After FDA Approval or Rejection?
An FDA decision is one of the biggest catalysts a biotech stock faces. But the reaction is not as simple as “approval up, rejection down.” Here is what tends to happen after an FDA decision, and why.
After an approval
Approval is usually a positive catalyst, but the size of the move depends heavily on what the market already expected. If approval was widely anticipated and priced in, the stock may barely move — or even fall on “sell the news.” If approval was in doubt, the pop can be large. The label matters too: a broad label supports bigger commercial expectations than a narrow one.
In BioRadar’s data on how biotech stocks move around FDA decisions, the average decision-day move was modest and the average five-day move was slightly negative — evidence that pre-event run-ups often fade after the catalyst, even on good outcomes.
After a Complete Response Letter
A Complete Response Letter — the FDA declining to approve in the current form — is usually a sharp negative. Stocks can gap down 40% or more, especially when approval was expected. The severity depends on the reason: a fixable manufacturing issue is less damaging than a CRL requiring a new Phase 3 trial, which can take years and force the company to raise capital, adding dilution.
Why approvals don’t always send a stock up
- It was priced in. Efficient markets discount likely outcomes in advance.
- Sell the news. Traders who bought the run-up take profits on the event.
- Narrow label or tough reimbursement. Approval is not the same as commercial success.
- Financing overhang. The company may raise capital to fund the launch.
The run-up then fade pattern
Across many events, biotech stocks have tended to rise into the decision and give some back afterwards. That is why understanding the setup — how much is priced in, how strong the data were, and the company’s cash position — matters more than the binary label of the outcome. Averages also mask the tails: individual events can move far more than the typical case in either direction.
How to prepare
Before a decision, define your plan for both outcomes. Know the company’s cash runway, whether an advisory committee weighed in, and what the market is pricing. BioRadar tracks upcoming FDA decisions with an approval-probability score and cash-runway analysis so you can assess the setup before the event, not react to it after.
Frequently asked questions
Do biotech stocks always go up after FDA approval?
No. Approval is usually positive, but if it was widely expected and priced in, the stock may barely move or even fall on “sell the news.” A narrow label, reimbursement concerns, or the need to raise capital for launch can also mute or reverse the reaction. The move depends on expectations, not just the approval itself.
How much does a stock drop after a Complete Response Letter?
It varies, but Complete Response Letters are usually sharp negatives and can gap a stock down 40% or more when approval was expected. The severity depends on the reason: a fixable manufacturing issue is less damaging than a CRL requiring another Phase 3 trial, which can take years and force dilutive financing.
Why did a biotech stock fall even though the drug was approved?
Usually because the approval was already priced in, so traders sold the news, or because the approved label was narrower than hoped, reimbursement looks difficult, or the company signalled it needs to raise capital to fund the launch. Approval and commercial success are not the same thing.